To solve this problem, the use of blood as a liquid biopsy containing circulating tumor cells (CTC), immune relevant or tumor-associated molecules, especially soluble IC molecules such as sHLA-G, represents a promising platform to establish surrogate markers for the disease monitoring and prediction of outcome in cancer. This evidence concerns the gene HLA-G and neoplasm.